What do systematic reviews say?

Valgus knee brace vs no brace

The review found no eligible studies for this question.

• Braces and orthoses for treating osteoarthritis of the knee 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Lateral wedge insole vs neutral insole

The review found no eligible studies for this question.

• Braces and orthoses for treating osteoarthritis of the knee 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Valgus knee brace vs lateral wedge insole

The review found no eligible studies for this question.

• Braces and orthoses for treating osteoarthritis of the knee 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

The review found no eligible studies for this question.

• TNF‐alpha inhibitors for ankylosing spondylitis 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

High‐dose corticosteroids vs moderate‐dose or no corticosteroids

High‐dose corticosteroids probably leads to higher serious adverse events compared with moderate‐dose or no corticosteroids (moderate certainty).

• Interventions for the treatment of metastatic extradural spinal cord compression in adults 2015 · Cochrane Headline outcomes only
  RR 8.02 [1.03, 62.37]
  2 studies · 77 participants
  Moderate

Type I Interferons vs placebo

Type I Interferons showed no clear difference in serious adverse events compared with placebo (low certainty).

• Type I interferons for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
  RR 0.74 [0.13, 4.14]
  4 studies · 468 participants
  Low

Topical NSAIDs vs topical placebo

• Topical NSAIDs for acute musculoskeletal pain in adults 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Low

Budesonide MMX® 6 mg vs placebo

Budesonide MMX® 6 mg showed no clear difference in serious adverse events compared with placebo (low certainty).

• Oral budesonide for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
  RR 0.63 [0.21, 1.91]
  2 studies · 512 participants
  Low

Budesonide vs mesalamine

Budesonide showed no clear difference in serious adverse events compared with mesalamine (low certainty).

• Oral budesonide for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
  RR 0.75 [0.17, 3.28]
  1 study · 254 participants
  Low

Budesonide MMX® 9 mg vs Entocort EC 9mg

Budesonide MMX® 9 mg showed no clear difference in serious adverse events compared with entocort EC 9mg (low certainty).

• Oral budesonide for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
  RR 3.94 [0.45, 34.74]
  1 study · 254 participants
  Low

Budesonide MMX® 9 mg vs placebo

Budesonide MMX® 9 mg showed no clear difference in serious adverse events compared with placebo (low certainty).

• Oral budesonide for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
  RR 0.88 [0.33, 2.4]
  2 studies · 513 participants
  Low

Intervention not reported

The intervention showed no clear difference in serious adverse events (moderate certainty).

• Addition of long‐acting beta₂‐agonists to inhaled corticosteroids for chronic asthma in children 2015 · Cochrane Headline outcomes only
  RR 1.54 [0.81, 2.94]
  7 studies · 1343 participants
  Moderate

Intervention not reported

The intervention showed no clear difference in serious adverse events (moderate certainty).

• Addition of long‐acting beta₂‐agonists to inhaled corticosteroids for chronic asthma in children 2015 · Cochrane Headline outcomes only
  RR 1.17 [0.75, 1.85]
  16 studies · 4022 participants
  Moderate

Intermittent LTRA vs placebo

The review found no eligible studies for this question.

• Leukotriene receptor antagonists as maintenance and intermittent therapy for episodic viral wheeze in children 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Maintenance LTRA vs placebo

The review found no eligible studies for this question.

• Leukotriene receptor antagonists as maintenance and intermittent therapy for episodic viral wheeze in children 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

• Milnacipran for pain in fibromyalgia in adults 2015 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 2378 participants
  Low

Intervention not reported

• Multidisciplinary rehabilitation after primary brain tumour treatment 2015 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 106 participants
  GRADE not reported

Intervention not reported

The intervention showed no clear difference in serious adverse events (moderate certainty).

• Latrepirdine for Alzheimer's disease 2015 · Cochrane Headline outcomes only
  RR 0.86 [0.55, 1.35]
  4 studies · 1034 participants
  Moderate

Indacaterol vs placebo

Indacaterol showed no clear difference in serious adverse events compared with placebo (moderate certainty).

• Indacaterol, a once‐daily beta₂‐agonist, versus twice‐daily beta₂‐agonists or placebo for chronic obstructive… 2015 · Cochrane Headline outcomes only
  OR 1 [0.82, 1.23]
  9 studies · 6065 participants
  Moderate

Transurethral radiofrequency collagen denaturation vs no treatment/sham

• Transurethral radiofrequency collagen denaturation for the treatment of women with urinary incontinence 2015 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 173 participants
  Low